S&P Global Market Intelligence presents a weekly rundown of recent executive changes at pharmaceutical, biotech and life sciences companies.
* James Robinson became president and COO of Alkermes PLC. He will lead the Dublin-based company's global commercial, business development, and human resources functions as it expands its commercial portfolio to advance treatments for central nervous system disorders.
* Exact Sciences Corp. appointed Paul Limburg co-chief medical officer. Limburg is a gastroenterologist and a professor of medicine at Mayo Clinic, a U.S.-based nonprofit medical practice and medical research group.
* Global Blood Therapeutics Inc. said it appointed David Johnson as its chief commercial officer, effective March 12. Johnson will create and lead the biotechnology company's commercial operations and will be responsible for building and leading sales, marketing, business analytics and market access.
* Zai Lab Ltd. named Billy Cho CFO. Cho previously served Citigroup as managing director and head of Asia Healthcare Investment Banking.
* BerGenBio ASA appointed Rune Skeie CFO. Skeie was previously CFO of REMA Franchise Norge AS.
* Peter Zorn stepped down from his positions as chief corporate officer, general counsel and secretary of Albireo Pharma Inc., effective April 1.
* Aeterna Zentaris Inc. named James Clavijo CFO. Most recently, Clavijo was CFO of Tri-Source Pharma.
* Josef von Rickenbach will retire as CEO of PAREXEL International Corp. Von Rickenbach co-founded the company in 1982 and has since served as chairman and CEO. He will retain his chairman position. The company appointed Jamie Macdonald to replace von Rickenbach, effective March 15.
* Tetraphase Pharmaceuticals Inc. promoted Chief Commercial Officer Larry Edwards to COO.
* Breathtec Biomedical Inc. appointed Christopher Moreau as its CEO. Moreau is CEO of NASH Pharmaceuticals Inc., a privately held drug development company.
* Alliance Pharma PLC said its founder John Dawson will step down as CEO but will remain on the company's board as a nonexecutive director. Peter Butterfield, the drugmaker's deputy chief executive, will become permanent CEO May 1.